Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|January 5, 2011
Major Depressive Disorder: A Case Study
This 10-minute video takes viewers couch-side to learn about the case of a young woman with trouble sleeping.
Advertisement
KSU Abnormal Psych Class Project: Video Blog for Major Depressive Disorder.
Advertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
4
Why Clinicians Should Not Wait to Augment Inadequate Response in MDD
5